We use cookies to customise content for your subscription and for analytics.
If you continue to browse Lexology, we will assume that you are happy to receive all our cookies. For further information please read our Cookie Policy.

Search results

Order by: most recent most popular relevance



Results: 1-10 of 346

USPTO Patent Eligibility Guidance In View Of CellzDirect And Sequenom
  • Foley & Lardner LLP
  • USA
  • July 18 2016

On July 14, 2016, the USPTO issued a Memorandum to the Patent Examining Corps on patent eligibility in view of recent court decisions. The July 2016


En Banc CAFC Requires UCC Sale For On Sale Bar
  • Foley & Lardner LLP
  • USA
  • July 19 2016

In an en banc decision issued in The Medicines Company v. Hospira, Inc., the Federal Circuit determined that in order for a commercial transaction to


Janssen Seeks Injunction Against Remicade Biosimilar Based On Cell Culture Patent
  • Foley & Lardner LLP
  • USA
  • July 14 2016

In a complaint filed June 14, 2016, Janssen Biotech Inc. seeks a preliminary injunction that would bar Celltrion and Hospira from selling the


CAFC Finds Cryopreservation Method Patent Eligible
  • Foley & Lardner LLP
  • USA
  • July 7 2016

The Federal Circuit ruled that the cryopreservation methods at issue in Rapid Litigation Mgmt. Ltd. v. CellzDirect Inc., are patent eligible under 35


The PRICED Act Would Expedite Biosimilar Market Entry
  • Foley & Lardner LLP
  • USA
  • July 12 2016

Although the 12-year exclusivity period for original biologic products was a heavily negotiated provision of the Biologics Price Competition and


Federal Circuit Requires 180 Day Notice For All Biosimilars, Even After Patent Dance
  • Foley & Lardner LLP
  • USA
  • July 6 2016

In Amgen v. Apotex, the Federal Circuit rejected Apotex's arguments that the 180-day pre-marketing notice requirement does not apply to biosimilar


Will The Celsis Appeal Put An End To 101 Rejections Of Laboratory Method Claims?
  • Foley & Lardner LLP
  • USA
  • April 26 2016

On April 5, 2016, the Federal Circuit heard oral arguments in Rapid Litigation Mgmt. Ltd. v. CellzDirect Inc., where the U.S. District Court for the


CAFC Affirms Finacea Gel Infringement Under Doctrine Of Equivalents
  • Foley & Lardner LLP
  • USA
  • May 24 2016

In Intendis GmbH v. Glenmark Pharmaceuticals Inc., USA, the Federal Circuit affirmed the district court decision that found infringement under the


Amgen And Sandoz Do The Biosimilar Patent Dance Over Neulasta
  • Foley & Lardner LLP
  • USA
  • May 17 2016

Amgen Inc. has filed a complaint under the Biologics Price Competition and Innovation Act (BPCIA), asserting that a biosimilar application filed by


Court Invalidates Improper Multiple Dependent Claims
  • Foley & Lardner LLP
  • USA
  • June 30 2016

In Trustees of the University of Pennsylvania v. Eli Lilly and Co., the U.S. District Court for the Eastern District of Pennsylvania refused to